Assembly Biosciences, Inc. · SWB:V7B

Assembly Biosciences, Inc. financial statements

Assembly Biosciences, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue72.3M28.5M7.16M06.25M79.1M16.0M14.8M9.02M0
Cost of revenue129.0K55.9M48.9M498.0K466.0K101.3M85.8M72.7M44.2M80.3K
Gross profit72.2M-27.4M-41.7M-498.0K6.25M-22.2M16.0M-57.9M-35.2M-80.3K
Research and development64.8M55.9M48.9M70.0M68.5M106.8M85.8M72.7M44.2M33.1M
Selling, general and administrative19.6M18.0M22.9M24.1M28.8M36.9M32.9M34.8M17.0M12.2M
Operating income-12.1M-45.4M-64.6M-94.1M-132.7M-64.8M-102.7M-92.7M-52.2M-45.3M
Depreciation and amortization129.0K129.0K450.0K498.0K466.0K691.0K494.0K643.0K219.0K80.0K
EBITDA-12.0M-45.3M-64.2M-93.6M-132.2M-64.1M-102.2M-92.1M-52.0M-45.2M
Interest expense498.0K82.5M2.62M4.80M000
Income before tax-6.12M-39.8M-61.2M-93.1M-132.4M-62.2M-98.4M-89.7M-51.9M-44.9M
Income tax0330.0K33.0K0-2.53M0-774.0K1.10M-9.05M-618.0K
Net income-6.12M-40.2M-61.2M-93.1M-129.9M-62.2M-97.6M-90.8M-42.8M-44.3M
Earnings per share, basic-0.55-6.69-13.38-23.08-3.00-1.75-3.72-3.98-2.41-2.57
Earnings per share, diluted-0.55-6.69-13.38-23.08-3.00-1.75-3.72-3.98-2.41-2.57

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents58.5M38.3M19.8M52.4M45.6M59.4M46.7M41.5M82.0M28.6M
Short-term investments189.7M73.7M110.4M39.2M101.0M157.0M227.3M176.6M37.9M24.4M
Receivables974.0K043.0K944.0K336.0K1.23M3.37M2.43M2.27M0
Inventory-3.20M1100110
Current assets254.5M115.5M133.8M97.0M154.2M224.5M282.8M222.5M123.1M53.6M
Property, plant and equipment221.0K284.0K385.0K743.0K1.14M1.60M1.83M557.0K860.0K214.7K
Goodwill012.6M12.6M12.6M12.6M12.6M
Total assets257.6M119.2M136.8M101.8M191.1M283.3M339.9M268.0M169.3M98.1M
Accounts payable1.17M585.0K461.0K2.49M2.66M4.60M1.73M3.69M2.12M2.37M
Current liabilities48.8M47.8M39.2M16.3M16.1M24.4M24.4M18.5M13.5M7.12M
Long-term debt00
Total debt2.63M3.09M2.34M3.46M6.48M10.1M12.3M
Total liabilities50.8M85.8M95.7M19.1M22.1M42.7M66.7M57.4M56.2M18.2M
Shareholders' equity206.8M33.4M41.1M82.7M168.9M240.6M273.2M210.7M113.1M79.9M
Shares outstanding15.9M7.46M5.48M4.07M48.1M34.0M32.6M25.5M20.1M17.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-41.1M-51.1M22.7M-84.5M-93.4M-63.0M-84.1M-65.0M1.86M-34.9M
Capital spending-66.0K-28.0K-255.0K-102.0K-3.10M-470.0K-1.55M-340.0K-865.0K-147.0K
Free cash flow-41.2M-51.1M22.5M-84.6M-96.5M-63.4M-85.6M-65.3M995.0K-35.0M
Cash from investing-113.5M40.2M-69.1M90.6M26.5M68.1M-50.3M-135.4M-15.6M36.2M
Cash from financing174.7M29.4M13.8M614.0K53.1M7.60M139.6M159.8M67.2M153.0K
Dividends paid00
Share buybacks614.0K7.60M139.6M159.8M67.2M152.6K
Change in cash20.1M18.5M-32.6M6.79M-13.8M12.7M5.26M-40.6M53.5M1.47M